Hepatocellular carcinoma: recent advances and emerging medical therapies.

F1000Res · 2020 · PMC7308880 · PMID 32595940

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A similar response rate and improvements in OS, objective response rate, and complete response rate were confirmed in the subsequent head-to-head comparison against sorafenib as first-line therapy in advanced HCC (CheckMate 459), but the primary endpoint of OS did not reach statistical significance 47 .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.